The company has earmarked a total investment of around Rs 30 crore
Lincoln Pharmaceuticals plans to launch Cephalosporin products and has acquired a facility in Mehsana, Gujarat for the same. The plant will cater to all the Cephalosporin products i.e. Tablet, Capsule, Dry syrup and Injectable.
The company is in the process of applying for WHO GMP Certifications for the facility and expects to receive the same by December 2021. There are plans to manufacture 20 plus Cephalosporin products and is planning to start product registration soon for the domestic and exports market.
Cephalosporin is a bactericidal, broad-spectrum, and β-lactam antibiotic originally derived from fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis and others.
Mahendra Patel, MD, Lincoln Pharmaceuticals, said, “The entire expansion for Cephalosporin products will be funded from internal accruals. The company has earmarked a total investment of around Rs 30 crore for the expansion. We expect commercial production of the Cephalosporin products by March 2022. In the next three years, the facility is expected to contribute sales of around Rs 150 crore from domestic markets as well as exports.”
